Is obsessive-compulsive disorder an anxiety disorder?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 3, 2006, Pages 338-352

  Bartz, Jennifer A ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorder; Nosology; Obsessive compulsive disorder (OCD); Obsessive compulsive spectrum

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOZAPINE; FLUOXETINE; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; AUTISM; BIOLOGY; BODY DYSMORPHIC DISORDER; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EATING DISORDER; FAMILY STUDY; HUMAN; NERVOUS SYSTEM; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; POSTTRAUMATIC STRESS DISORDER; REVIEW; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ANXIETY DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER;

EID: 33646038238     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.003     Document Type: Review

References (146)

1. Adams K.H., Hansen E.S., Pinborg L.H., Hasselbalch S.G., Svarer C., Holm S., et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 8 (2005) 1-11
2. Albucher R.C., and Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res 36 (2002) 355-367
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth ed., rev. (2000), Author, Washington, DC
4. Anthony E.W., and Nevins M.E. Anxiolytic-like effects of N-methyl-d-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250 (1993) 317-324
5. Avanzi M., Uber E., and Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 25 (2004) 98-101
6. Ballenger J.C. Current treatments of the anxiety disorders in adults. Biol Psychiatry 46 (1999) 1579-1594
7. Bellodi L., Cavallini M.C., Bertelli S., Chiapparino D., Riboldi C., and Smeraldi E. Morbidity risk for obsessive-compulsive spectrum disorders in first-degree relatives of patients with eating disorders. Am J Psychiatry 158 (2001) 563-569
8. Bergh C., Eklund T., Sodersten P., and Nordin C. Altered dopamine function in pathological gambling. Psychol Med 27 (1997) 473-475
9. Bienvenu O.J., Samuels J.F., Riddle M.A., Hoehn-Saric R., Liang K.Y., Cullen B.A., et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry 48 (2000) 287-293
10. Birbaumer N., Grodd W., Diedrich O., Klose U., Erb M., Lotze M., et al. fMRI reveals amygdala activation to human faces in social phobics. NeuroReport 9 (1998) 1223-1226
11. Bisaga A., Katz J.L., Antonini A., Wright C.E., Margouleff C., Gorman J.M., et al. Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry 155 (1998) 1178-1183
12. Black D.W., Goldstein R.B., Noyes R., and Blum N. Compulsive behaviors and obsessive-compulsive disorder (OCD): lack of a relationship between OCD, eating disorders, and gambling. Compr Psychiatry 35 (1994) 145-148
13. Black D.W., Goldstein R.B., Noyes R., and Blum N. Psychiatric disorders in relatives of probands with obsessive-compulsive disorder and co-morbid major depression or generalized anxiety. Psychiatr Genet 5 (1995) 37-41
14. Blanco C., Orensanz-Munoz L., Blanco-Jerez C., and Saiz-Ruiz J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 153 (1996) 119-121
15. Blaszczynski A. Pathological gambling and obsessive-compulsive spectrum disorders. Psychol Rep 84 (1999) 107-113
16. Bradwejn J., Koszycki D., and Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48 (1991) 603-610
17. Bradwejn J., Koszycki D., Couetoux du Tertre A., van Megen H., den Boer J., and Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51 (1994) 486-493
18. Breiter H.C., Rauch S.L., Kwong K.K., Baker J.R., Weisskoff R.M., Kennedy D.N., et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 53 (1996) 595-606
19. Bremner J.D., Randall P., Vermetten E., Staib L., Bronen R.A., Mazure C., et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse-a preliminary report. Biol Psychiatry 41 (1997) 23-32
20. Brown T.A., Campbell L.A., Lehman C.L., Grisham J.R., and Mancill R.B. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 110 (2001) 585-599
21. Buxbaum J.D., Silverman J., Keddache M., Smith C.J., Hollander E., Ramoz N., et al. Linkage analysis for autism in a subset of families with obsessive-compulsive behaviors: evidence for an autism susceptibility gene on chromosome 1 and further support for susceptibility genes on chromosome 6 and 19. Mol Psychiatry 9 (2004) 144-150
22. Carter A.S., Pollock R.A., Suvak M.K., and Pauls D.L. Anxiety and major depression comorbidity in a family study of obsessive-compulsive disorder. Depress Anxiety 20 (2004) 165-174
23. Cath D.C., Spinhoven P., Hoogduin C.A., Landman A.D., van Woerkom T.C., van de Wetering B.J., et al. Repetitive behaviors in Tourette's syndrome and OCD with and without tics: what are the differences?. Psychiatry Res 101 (2001) 171-185
24. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand 417 (2003) 38-50 [Suppl.]
25. Charney D.S., Heninger G.R., and Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41 (1984) 751-763
26. Chugani D.C. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 7 Suppl. 2 (2002) S16-S17
27. Dale R.C. Autoimmunity and the basal ganglia: new insights into old diseases. QJM 96 (2003) 183-191
28. DeCaria C.M., Hollander E., Grossman R., Wong C.M., Mosovich S.A., and Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 57 Suppl. 8 (1996) S80-S83 [discussion 83-84]
29. De Cristofaro M.T., Sessarego A., Pupi A., Biondi F., and Faravelli C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry 33 (1993) 505-512
30. Denys D., Tenney N., van Megen H.J., de Geus F., and Westenberg H.G. Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. J Affect Disord 80 (2004) 155-162
31. Denys D., Zohar J., and Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65 Suppl. 14 (2004) S11-S17
32. Drevets W.C., Burton H., Videen T.O., Snyder A.Z., Simpson Jr. J.R., and Raichle M.E. Blood flow changes in human somatosensory cortex during anticipated stimulation. Nature 373 (1995) 249-252
33. du Toit P.L., van Kradenburg J., Niehaus D., and Stein D.J. Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry 42 (2001) 291-300
34. Eisen J.L., and Rasmussen S.A. Phenomenology of obsessive-compulsive disorder. In: Stein D.J., and Hollander E. (Eds). Textbook of anxiety disorders (2002), American Psychiatric Publishing, Washington, DC 173-189
35. Fallon B.A., Liebowitz M.R., Salman E., Schneier F.R., Jusino C., Hollander E., et al. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 13 (1993) 438-441
36. Fassino S., Leombruni P., Daga G., Brustolin A., Migliaretti G., Cavallo F., et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 12 (2002) 453-459
37. Fendt M., Koch M., and Schnitzler H.U. Lesions of the central gray block conditioned fear as measured with the potentiated startle paradigm. Behav Brain Res 74 (1996) 127-134
38. Ferrarese C., Appollonio I., Frigo M., Perego M., Piolti R., Trabucchi M., et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 82 (1990) 169-173
39. Fireman B., Koran L.M., Leventhal J.L., and Jacobson A. The prevalence of clinically recognized obsessive-compulsive disorder in a large health maintenance organization. Am J Psychiatry 158 (2001) 1904-1910
40. Foa E.B., and Kozak M.J. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry 152 (1995) 90-96
41. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 33 (2003) 365-382
42. Goddard A.W., Mason G.F., Appel M., Rothman D.L., Gueorguieva R., Behar K.L., et al. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 161 (2004) 2186-2193
43. Goodman W.K., McDougle C.J., Price L.H., Riddle M.A., Pauls D.L., and Leckman J.F. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?. J Clin Psychiatry 51 (1990) S36-S43 [Suppl., discussion, 55-58]
44. Goodman W.K., Price L.H., Delgado P.L., Palumbo J., Krystal J.H., Nagy L.M., et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47 (1990) 577-585
45. Goudriaan A.E., Oosterlaan J., de Beurs E., and Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 28 (2004) 123-141
46. Grados M.A., Riddle M.A., Samuels J.F., Liang K.Y., Hoehn-Saric R., Bienvenu O.J., et al. The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: the Hopkins OCD family study. Biol Psychiatry 50 (2001) 559-565
47. Grados M.A., Walkup J., and Walford S. Genetics of obsessive-compulsive disorders: new findings and challenges. Brain Dev 25 Suppl. 1 (2003) S55-S61
48. Greer J.M., and Capecchi M.R. Hoxb8 is required for normal grooming behavior in mice. Neuron 33 (2002) 23-34
49. Gunstad J., and Phillips K.A. Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry 44 (2003) 270-276
50. Gurvits T.V., Gilbertson M.W., Lasko N.B., Orr S.P., and Pitman R.K. Neurological status of combat veterans and adult survivors of sexual abuse PTSD. Ann NY Acad Sci 821 (1996) 468-471
51. Harel Z., Hallett J., Riggs S., Vaz R., and Kiessling L. Antibodies against human putamen in adolescents with anorexia nervosa. Int J Eat Disord 29 (2001) 463-469
52. Harvey B.H., Brink C.B., Seedat S., and Stein D.J. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 21-32
53. Hoehn-Saric R., Schlund M.W., and Wong S.H. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res 131 (2004) 11-21
54. Hollander E. Obsessive-compulsive related disorders (1993), American Psychiatric Press, Washington, DC
55. Hollander E., and Wong C.M. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 56 Suppl. 4 (1995) 3-6
56. Hollander E., DeCaria C.M., Nitescu A., Gully R., Suckow R.F., Cooper T.B., et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49 (1992) 21-28
57. Hollander E., Kwon J., Weiller F., Cohen L., Stein D.J., DeCaria C., et al. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Res 79 (1998) 213-217
58. Hollander E., Allen A., Kwon J., Aronowitz B., Schmeidler J., Wong C., et al. Clomipramine vs. desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56 (1999) 1033-1039
59. Hollander E., Kaplan A., Cartwright C., and Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 15 (2000) 132-135
60. Hollander E., DeCaria C.M., Finkell J.N., Begaz T., Wong C.M., and Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 47 (2000) 813-817
61. Hollander E., King A., Delaney K., Smith C.J., and Silverman J.M. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res 117 (2003) 11-16
62. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28 (2003) 193-198
63. Hollander E., Friedberg J.P., Wasserman S., Yeh C.-C., and Iyengar R. The case for the OCD spectrum. In: Abramowitz J.S., and Houts A.C. (Eds). Handbook of controversial issues in obsessive-compulsive disorder (2005), Kluwer Academic Press
64. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 (2005) 582-589
65. Hollander E., Pallanti S., Allen A., Sood E., and Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?. Am J Psychiatry 162 (2005) 137-145
66. Hollander E., Anagnostou E., Chaplin W., Esposito K., Haznedar M.M., Licalzi E., et al. Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol Psychiatry 58 (2005) 226-232
67. Hu X., Giotakis O., Li T., Karwautz A., Treasure J., and Collier D.A. Association of the 5-HT2c gene with susceptibility and minimum body mass index in anorexia nervosa. NeuroReport 14 (2003) 781-783
68. Insel T.R., O'Brien D.J., and Leckman J.F. Oxytocin, vasopressin, and autism: is there a connection?. Biol Psychiatry 45 (1999) 145-157
69. Jaisoorya T.S., Reddy Y.C., and Srinath S. The relationship of obsessive-compulsive disorder to putative spectrum disorders: results from an Indian study. Compr Psychiatry 44 (2003) 317-323
70. Jenck F., Moreau J.L., and Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57 (1995) 181-191
71. Jenike M.A. Illnesses related to obsessive-compulsive disorder. In: Jenike M.A., Baer L.B., and Minichiello W.E. (Eds). Obsessive compulsive disorders: theory and management. Second ed. (1990), Year Book Medical 39-60
72. Jetty P.V., Charney D.S., and Goddard A.W. Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am 24 (2001) 75-97
73. Kaplan A., and Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 54 (2003) 1111-1118
74. Kaye W.H., Nagata T., Weltzin T.E., Hsu L.K., Sokol M.S., McConaha C., et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 49 (2001) 644-652
75. Kent J.M., and Rauch S.L. Neurocircuitry of anxiety disorders. Curr Psychiatry Rep 5 (2003) 266-273
76. Kim S.W., Grant J.E., Adson D.E., Shin Y.C., and Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 63 (2002) 501-507
77. Knutson B., Wolkowitz O.M., Cole S.W., Chan T., Moore E.A., Johnson R.C., et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155 (1998) 373-379
78. LaSalle V.H., Cromer K.R., Nelson K.N., Kazuba D., Justement L., and Murphy D.L. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depress Anxiety 19 (2004) 163-173
79. Lilenfeld L.R., Kaye W.H., Greeno C.G., Merikangas K.R., Plotnicov K., Pollice C., et al. A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. Arch Gen Psychiatry 55 (1998) 603-610
80. Lydiard R.B. The role of GABA in anxiety disorders. J Clin Psychiatry 64 Suppl. 3 (2003) 21-27
81. Maron E., Kuikka J.T., Shlik J., Vasar V., Vanninen E., and Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res 132 (2004) 173-181
82. Massana G., Serra-Grabulosa J.M., Salgado-Pineda P., Gasto C., Junque C., Massana J., et al. Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. NeuroImage 19 (2003) 80-90
83. Mathew S.J., Mao X., Coplan J.D., Smith E.L., Sackeim H.A., Gorman J.M., et al. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry 161 (2004) 1119-1121
84. McDougle C.J., Goodman W.K., and Price L.H. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 55 (1994) S24-S31 [Suppl.]
85. McDougle C.J., Kresch L.E., Goodman W.K., Naylor S.T., Volkmar F.R., Cohen D.J., et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152 (1995) 772-777
86. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., and Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 (1996) 1001-1008
87. McDougle C.J., Barr L.C., Goodman W.K., and Price L.H. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24 (1999) 1-24
88. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., and Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57 (2000) 794-801
89. McElroy S.L., Phillips K.A., and Keck P.E. Obsessive compulsive spectrum disorder. J Clin Psychiatry 55 Suppl. 10 (1994) 33-51
90. Meyer G., Schwertfeger J., Exton M.S., Janssen O.E., Knapp W., Stadler M.A., et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 29 (2004) 1272-1280
91. Nestadt G., Samuels J., Riddle M.A., Liang K.Y., Bienvenu O.J., Hoehn-Saric R., et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study. Psychol Med 31 (2001) 481-487
92. Nestadt G., Addington A., Samuels J., Liang K.Y., Bienvenu O.J., Riddle M., et al. The identification of OCD-related subgroups based on comorbidity. Biol Psychiatry 53 (2003) 914-920
93. Neumeister A., Bain E., Nugent A.C., Carson R.E., Bonne O., Luckenbaugh D.A., et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24 (2004) 589-591
94. Nordahl T.E., Semple W.E., Gross M., Mellman T.A., Stein M.B., Goyer P., et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 3 (1990) 261-272
95. Nutt D.J., Glue P., Lawson C., and Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 47 (1990) 917-925
96. Pallanti S., Quercioli L., Rossi A., and Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry 60 (1999) 819-823
97. Park S., Como P.G., Cui L., and Kurlan R. The early course of the Tourette's syndrome clinical spectrum. Neurology 43 (1993) 1712-1715
98. Peterson B.S., Thomas P., Kane M.J., Scahill L., Zhang H., Bronen R., et al. Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry 60 (2003) 415-424
99. 2 inhalation in normal subjects and patients with panic disorder determined with [15O]water and PET. J Anxiety Disord 16 (2002) 247-258
100. Raleigh M.J., Brammer G.L., McGuire M.T., and Yuwiler A. Dominant social status facilitates the behavioral effects of serotonergic agonists. Brain Res 348 (1985) 274-282
101. Ramacciotti C.E., Coli E., Paoli R., Marazziti D., and Dell'Osso L. Serotonergic activity measured by platelet [3H]paroxetine binding in patients with eating disorders. Psychiatry Res 118 (2003) 33-38
102. Rasmusson AM, Vythilingam M, Morgan CA. The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr 2003; 8: 651-656, 665-667.
103. Rauch S.L., Jenike M.A., Alpert N.M., Baer L., Breiter H.C., Savage C.R., et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51 (1994) 62-70
104. Rauch S.L., Phillips K.A., Segal E., Makris N., Shin L.M., Whalen P.J., et al. A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder. Psychiatry Res 122 (2003) 13-19
105. Reiman E.M., Raichle M.E., Butler F.K., Herscovitch P., and Robins E. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature 310 (1984) 683-685
106. Reiman E.M., Raichle M.E., Robins E., Mintun M.A., Fusselman M.J., Fox P.T., et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 46 (1989) 493-500
107. Richard I.H., Schiffer R.B., and Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 8 (1996) 383-392
108. Richter M.A., Summerfeldt L.J., Antony M.M., and Swinson R.P. Obsessive-compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders. Depress Anxiety 18 (2003) 118-127
109. Rocca P., Beoni A.M., Eva C., Ferrero P., Zanalda E., and Ravizza L. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol Psychiatry 43 (1998) 767-773
110. Roiser J.P., McLean A., Ogilvie A.D., Blackwell A.D., Bamber D.J., Goodyer I., et al. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology 30 (2005) 775-785
111. Santonastaso P., Friederici S., and Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol 11 (2001) 143-150
112. Saxena S., and Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 23 (2000) 563-586
113. Saxena S., Brody A.L., Schwartz J.M., and Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Brit J Psychiatry 35 (1998) 26-37
114. Saxena S., Bota R.G., and Brody A.L. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 6 (2001) 82-101
115. Scahill L., Leckman J.F., Schultz R.T., Katsovich L., and Peterson B.S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60 (2003) 1130-1135
116. Sears L.L., Vest C., Mohamed S., Bailey J., Ranson B.J., and Piven J. An MRI study of the basal ganglia in autism. Prog Neuropsychopharmacol Biol Psychiatry 23 (1999) 613-624
117. Seedat S., Kesler S., Niehaus D.J., and Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11 (2000) 185-186
118. Sheehan D.V. Current concepts in the treatment of panic disorder. J Clin Psychiatry 60 Suppl. 18 (1999) 16-21
119. Shin L.M., Wright C.I., Cannistraro P.A., Wedig M.M., McMullin K., Martis B., et al. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry 62 (2005) 273-281
120. Singer H.S., Szymanski S., Giuliano J., Yokoi F., Dogan A.S., Brasic J.R., et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159 (2002) 1329-1336
121. Stein D.J. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 47 (2002) 296-304
122. Stein D.J., Bouwer C., and Maud C.M. Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Eur Arch Psychiatry Clin Neurosci 247 (1997) 234-236
123. Stein D.J., Van Heerden B., Wessels C.J., Van Kradenburg J., Warwick J., and Wasserman H.J. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 23 (1999) 1079-1099
124. Stein D.J., Westenberg H.G., and Liebowitz M.R. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 63 Suppl. 6 (2002) 12-19
125. Stewart R.S., Devous Sr. M.D., Rush A.J., Lane L., and Bonte F.J. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry 145 (1988) 442-449
126. Stojanov W., Karayanidis F., Johnston P., Bailey A., Carr V., and Schall U. Disrupted sensory gating in pathological gambling. Biol Psychiatry 54 (2003) 474-484
127. Straube T., Mentzel H.J., Glauer M., and Miltner W.H. Brain activation to phobia-related words in phobic subjects. Neurosci Lett 372 (2004) 204-208
128. Szechtman H., Sulis W., and Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112 (1998) 1475-1485
129. Targum S.D., and Marshall L.E. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28 (1989) 295-306
130. Thoren P., Asberg M., Bertilsson L., Mellstrom B., Sjoqvist F., and Traskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 37 (1980) 1289-1294
131. Thornton C., and Russell J. Obsessive compulsive comorbidity in the dieting disorders. Int J Eat Disord 21 (1997) 83-87
132. Tillfors M. Why do some individuals develop social phobia? A review with emphasis on the neurobiological influences. Nord J Psychiatry 58 (2004) 267-276
133. Tillfors M., Furmark T., Marteinsdottir I., Fischer H., Pissiota A., Langstrom B., et al. Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry 158 (2001) 1220-1226
134. Tizabi Y., Louis V.A., Taylor C.T., Waxman D., Culver K.E., and Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry 51 (2002) 164-171
135. Tynes L.L., White K., and Steketee G.S. Toward a new nosology of obsessive compulsive disorder. Compr Psychiatry 31 (1990) 465-480
136. Uys J.D., Stein D.J., Daniels W.M., and Harvey B.H. Animal models of anxiety disorders. Curr Psychiatry Rep 5 (2003) 274-281
137. van der Wee N.J., Stevens H., Hardeman J.A., Mandl R.C., Denys D.A., van Megen H.J., et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry 161 (2004) 2201-2206
138. Westenberg H.G., and Liebowitz M.R. Overview of panic and social anxiety disorders. J Clin Psychiatry 65 Suppl. 14 (2004) 22-26
139. Whiteside S.P., Port J.D., and Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 132 (2004) 69-79
140. Wignall E.L., Dickson J.M., Vaughan P., Farrow T.F., Wilkinson I.D., Hunter M.D., et al. Smaller hippocampal volume in patients with recent-onset posttraumatic stress disorder. Biol Psychiatry 56 (2004) 832-836
141. Winter H., and Irle E. Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. Am J Psychiatry 161 (2004) 2194-2200
142. Wu J.C., Buchsbaum M.S., Hershey T.G., Hazlett E., Sicotte N., and Johnson J.C. PET in generalized anxiety disorder. Biol Psychiatry 29 (1991) 1181-1199
143. Yehuda R., Southwick S.M., Krystal J.H., Bremner D., Charney D.S., and Mason J.W. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry 150 (1993) 83-86
144. Yehuda R., Siever L.J., Teicher M.H., Levengood R.A., Gerber D.K., Schmeidler J., et al. Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttraumatic stress disorder and major depressive disorder. Biol Psychiatry 44 (1998) 56-63
145. Zimmerman M., Breen R.B., and Posternak M.A. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 63 (2002) 44-48
146. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., and Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 44 (1987) 946-951